Pharma opens its new Paris premises at the Institut de la Vision, one
of Europe's major research centers dedicated to eye diseases.
collaboration will facilitate the accelerated development of new
therapies to benefit patients with impaired vision and suffering from
PARIS, NICE - December 9, 2008 - Iris
Pharma, the global specialist in preclinical and clinical ophthalmic
research, is cementing its partnership with the "Institut de la
Vision", with which it joined forces over a year ago. With the official
opening of this international center scheduled for December 11, an
R&D team from Iris Pharma is now on board, helping to underpin the
joint collaborative efforts of the academic and the industrial teams.
close ties constitute a first-rate acknowledgment of Iris
Pharma’s contribution, and crown almost 20 years of experience in
the field of vision-related diseases. Founded in 1989 by Pierre-Paul
Elena, a doctor in pharmacology and molecular & cellular biology,
Iris Pharma is today Europe's number one contract research organization
(CRO) and a world leader in the field of ophthalmology.
In the words of Prof. José-Alain Sahel, Director of the Institut de la Vision: “Our
European research center exclusively dedicated to eye diseases today
houses several academic and industrial teams specialized in the field
of vision, who wish to develop and validate their innovations relating
to therapeutic molecules, diagnostic tools and devices to improve the
daily lives of the partially sighted. This collaboration with Iris
Pharma is a major boon for the Institut de la Vision. Integrated within
an academic environment that is uncompromising where the scientific
issues are concerned, it provides us with comprehensive oversight of
the entire industry, from the major corporations to the innovative
startups, that will be so valuable for us. It is our guarantee of
maintaining a strategic approach when striking appropriate industrial
partnership deals. These kinds of partnerships are vital to the
culmination of our research when it comes to making available
treatments to patients."
Global public health issues
the aging of the population leading to a major and lasting increase in
vision-related diseases, the acceleration of scientific and
biotechnological progress in the field of ophthalmology holds out the
promise of major therapeutic innovations that are in the pipeline. The
close collaboration initiated between Iris Pharma and the Institut de
la Vision is intended to bring to fruition the promise of these
developments for partially sighted patients.
“Iris Pharma is custodian of a dual culture," explains Dr. Pierre-Paul Elena, “forged
on the one hand with the major pharmaceutical industrialists and, on
the other, with the most innovative biotechnological companies. By
joining forces with the Institut de la Vision, we complement its
exceptional resources with our cross-industrial expertise, which allows
us to act as an efficient intermediary between basic research, industry
and patient care."
The Institute brings its medical expertise to bear in particular
through its clinical investigation center, its investment in all forms
of eye disease at one of the top ophthalmology hospitals and its
network of clinicians and scientists.
Reconciling economic efficiency, R&D excellence and patient well-being
on its expertise and international reputation acquired in the service
of the major pharmaceutical groups, Iris Pharma is expert at managing
the entire continuum of ophthalmic drugs development.
Iris Pharma has also heavily invested in research programs targeting
breakthrough innovations (Age-Related Macular Degeneration (ARMD),
retinitis linked to diabetes, etc.). It will continue to pursue this
goal by taking part in the steering committee of the Institut de la
Vision, which will define the strategic lines of research.
“However important the economic
factors of our activity may be, the end goal remains above all making
treatments available for the well-being of patients," explains Dr. Elena.
“This is what really underlies our partnership with the teams of
the Institut de la Vision. The prospects for treatment that are made
possible by our research are fascinating, since they hold out the
promise of transforming the lives of patients with eye diseases in a
very short timeframe."
|About Iris Pharma:
Pharma is an independent French CRO that specializes in preclinical and
clinical research in the field of ophthalmology, and is based in the
Nice region. Founded in 1989 by Dr Pierre-Paul Elena, Iris Pharma
offers its services and expertise in the development of ophthalmic
drugs and ocular medical devices to the pharmaceutical industry,
biotechnology companies, and research institutes around the world. The
company has five main areas of activity: bio-analysis, pre-formulation,
preclinical studies and services, clinical trials (Phase I and IV and
medico-marketing surveys) and strategic consulting.
Recognized for the rigor and quality of its research, Iris Pharma has
been chosen by the European Vision Institute (EVI.CT.SE) as an
independent expert in Good Clinical Practice (GCP) for ophthalmic
research. Since 1995, Iris Pharma has been recognized by the AFSSAPS
(French Drug Agency) as a laboratory that complies with Good
Laboratory Practice (GLP).
In 2008, Iris Pharma took on six new employees, bringing its headcount
up to 50. Its ongoing projects make it a major figure in the
development of the local economy.
For further information: http://www.iris-pharma.com
About the Institut de la Vision:
Institut de la Vision is one of Europe’s largest research centers
dedicated exclusively to vision (Inserm center / Paris VI). Opened in
March 2008 in the Centre Hospitalier National d'Ophtalmologie (CHNO)
des Quinze-Vingts, in Paris, it encompasses a biomedical research
center (divided into four departments: Developmental Biology, Genetics,
Low-Level Vision, Therapy), the Clinical Research Center of the CHNO
des Quinze-Vingts (phase I to III clinical trials according to Good
Clinical Practice (GCP) and the guidelines in force) and a dozen major
industrialists (Essilor, Thea, Fovea Pharma, Horus Pharma, Visiotact,
IMI, Iris Pharma, Ardoyset).
For further information: http://www.institut-vision.org
Iris Pharma Contact
Les Nertières - Allée Hector Pintus
- 06610 La Gaude - France
Tél.: +33 4 93 59 49 59 - Fax: +33 4 93 59 49 50
- website: http://www.iris-pharma.com
Agence Yucatan - Annie-Florence Loyer
Tél. : +33 1 53 63 27 29 - Email : firstname.lastname@example.org
Institut de la Vision Contact
e-mail: email@example.com -